Stay updated on Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.

Latest updates to the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRecruitment status on the study page now indicates 'No longer looking for participants', signaling that enrollment is closed. New help and navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study), and the Intervention/Treatment header formatting was standardized, accompanied by a revision note (Revision: v3.6.0).SummaryDifference0.6%

- Check20 days agoChange DetectedFooter area updated to include a Moffitt Cancer Center Clinical Trials website link and the sponsor's institution name (H. Lee Moffitt Cancer Center and Research Institute), along with a 'Helpful Links Provided by' label. The page revision tag was updated from v3.5.4 to v3.5.5.SummaryDifference0.2%

- Check27 days agoChange DetectedThe deletions remove sponsor attribution blocks for the study (H. Lee Moffitt Cancer Center and Research Institute) and the reference to the Moffitt Clinical Trials website, as well as the 'Helpful Links Provided by' label. This changes how attribution and related navigation are presented on the page.SummaryDifference0.2%

- Check41 days agoChange DetectedThe page now shows Revision: v3.5.4, replacing the previous v3.5.3 label. This indicates a backend/template update to the study record display without changing substantive study details.SummaryDifference0.1%

- Check63 days agoChange DetectedThe page’s footer “Revision” version was updated from v3.5.2 to v3.5.3, reflecting a backend/site release rather than a change to the study record content.SummaryDifference0.1%

- Check70 days agoChange DetectedRevision: v3.5.2 updated from v3.5.0. No visible changes to study details or page content.SummaryDifference0.1%

Stay in the know with updates to Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.